Autoimmune Disease Diagnosis Market: Market Size & Forecast 2026

The autoimmune disease diagnosis market covers laboratory-based tests, point-of-care devices, and imaging services that detect antibodies and other biomarkers associated with over 80 recognized autoimmune conditions affecting roughly 50 million Americans alone, according to NIH estimates. North America currently leads the global market due to high healthcare spending, advanced laboratory infrastructure, and strong regulatory frameworks, while Asia-Pacific represents the fastest-growing regional segment as healthcare access expands.

• •The market is valued at approximately $6.28 billion in 2025, with prior-year comparisons showing growth from roughly $5.7 billion in 2024
• •Product categories span ELISA assays, immunoassays, western blotting, flow cytometry, and various autoimmune-specific test panels

Rising prevalence of autoimmune disorders forms the primary growth catalyst, with the CDC and NIH confirming increasing incidence rates across conditions including type 1 diabetes, inflammatory bowel disease, and multiple sclerosis over recent decades. Aging populations further contribute as autoimmune susceptibility increases with age, while sedentary lifestyles and environmental factors are also cited as potential accelerants.

• •Technological advancements in immunoassay sensitivity and multiplex testing capabilities enable earlier and more accurate disease detection
• •Growing patient awareness and physician screening protocols are expanding diagnostic volumes across both established and emerging markets
• •Expanding healthcare reimbursement policies for autoimmune testing are reducing financial barriers to diagnosis in multiple countries

By test type, the market is commonly segmented into routine autoimmune tests, systemic autoimmune disease tests, and organ-specific tests, with rheumatoid arthritis and thyroid disorder diagnostics representing the largest volume categories. Geographically, North America dominates with an estimated 35-40% market share, followed by Europe, while Asia-Pacific, Latin America, and the Middle East are each capturing growing shares as laboratory infrastructure investments accelerate.

• •Geographic distribution shows North America leading, followed by Europe, with Asia-Pacific emerging as the fastest-growing regional market segment
• •Regional variations in autoimmune prevalence are influenced by genetic factors, environmental exposures, and diagnostic capability differences across healthcare systems

What are the recent trends and outlook?

Emerging trends include the integration of artificial intelligence for pattern recognition in complex antibody profiling, the development of multiplex assays that test for multiple autoimmune markers simultaneously, and growing interest in point-of-care testing for specific antibody detection. Personalized medicine approaches and biomarker discovery efforts are expected to expand the diagnostic menu beyond current standard-of-care tests through 2030.

• •Advancements in mass cytometry and next-generation sequencing are enabling researchers to identify novel autoimmune subtypes and more precise disease stratification
• •Expansion of laboratory-developed tests and companion diagnostics for autoimmune conditions represents a meaningful near-term opportunity
• •The market is expected to reach between $10 billion and $17 billion by 2031-2034 depending on the forecasting model and assumed CAGR